NAD+ metabolism in age-related hearing loss

Aging and Disease

Volumn 5, Issue 2, 2014, Pages 150-159

  Kim, Hyung Jin ^a   Oh, Gi Su ^a   Choe, Seong Kyu ^a   Kwak, Tae Hwan ^b   Park, Raekil ^a   So, Hong Seob ^a  

^a Wonkwang University School of Medicine   (South Korea)

^b KTandG LIFE SCIENCES   (South Korea)

Author keywords

Age related hearing loss; Degenerative disorder; Metabolism; NAD+

Indexed keywords

EID: 84916931081     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: 10.14336/AD.2014.0500150     Document Type: Review

References (93)

1. Cacciatore F, Napoli C, Abete P, Marciano E, Triassi M, Rengo F (1999). Quality of life determinants and hearing function in an elderly population: Osservatorio Geriatrico Campano Study Group. Gerontology, 45:323-328.
2. Desai M, Pratt LA, Lentzner H, Robinson KN (2001). Trends in vision and hearing among older Americans. Aging Trends 2:1-8.
3. Van Eyken E, Van Camp G, Van Laer L (2007). The complexity of age-related hearing impairment: contributing environmental and genetic factors. Audiol Neurootol, 12:345-358.
4. Spongr VP, Flood DG, Frisina RD, Salvi RJ (1997). Quantitative measures of hair cell loss in CBA and C57BL/6 mice throughout their life spans. J Acoust Soc Am, 101:3546-3553.
5. Hequembourg S, Liberman MC (2001). Spiral ligament pathology: a major aspect of age-related cochlear degeneration in C57BL/6 mice. J Assoc Res Otolaryngol, 2:118-129.
6. + metabolism oxidative stress and Sirt1 activity in wistar rats. PLoS One, 6:e19194.
7. + metabolism in human tissue. PLoS One, 7:e42357.
8. Chen D, Bruno J, Easlon E, Lin SJ, Cheng HL, Alt FW et al (2008). Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev, 22:1753-1757.
9. Adam-Vizi V, Tretter L (2013). The role of mitochondrial dehydrogenases in the generation of oxidative stress. Neurochem Int, 62:757-763.
10. Murphy MP (2009). How mitochondria produce reactive oxygen species. Biochem J, 417:1-13.
11. Harman D (1956). Aging: a theory based on free radical and radiation chemistry. J Gerontol, 11:298-300.
12. Miquel J, Economos AC, Fleming J, Johnson JE, Jr. (1980). Mitochondrial role in cell aging. Exp Gerontol, 15:575-591.
13. Shigenaga MK, Hagen TM, Ames BN (1994). Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A, 91:10771-10778.
14. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE et al (2005). Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science, 309:481-484.
15. Fetoni AR, Picciotti PM, Paludetti G, Troiani D (2011). Pathogenesis of presbycusis in animal models: a review. Exp Gerontol, 46:413-425.
16. Liu XZ, Yan D (2007). Ageing and hearing loss. J Pathol, 211:188-197.
17. Pickles JO (2004). Mutation in mitochondrial DNA as a cause of presbyacusis. Audiol Neurootol, 9:23-33.
18. Singh T, Newman AB (2011). Inflammatory markers in population studies of aging. Ageing Res Rev, 10:319-329.
19. Woods JA, Wilund KR, Martin SA, Kistler BM (2012). Exercise, inflammation and aging. Aging Dis, 3:130-140.
20. Kregel KC, Zhang HJ (2007). An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Integr Comp Physiol, 292:R18-36.
21. Mitchell P, Gopinath B, McMahon CM, Rochtchina E, Wang JJ, Boyages SC et al (2009). Relationship of Type 2 diabetes to the prevalence, incidence and progression of age-related hearing loss. Diabet Med, 26:483-488.
22. Gates GA, Cobb JL, D'Agostino RB, Wolf PA (1993). The relation of hearing in the elderly to the presence of cardiovascular disease and cardiovascular risk factors. Arch Otolaryngol Head Neck Surg, 119:156-161.
23. Iwai H, Lee S, Inaba M, Sugiura K, Tomoda K, Yamashita T et al (2001). Prevention of accelerated presbycusis by bone marrow transplantation in senescence-accelerated mice. Bone Marrow Transplant, 28:323-328.
24. Fujioka M, Kanzaki S, Okano HJ, Masuda M, Ogawa K, Okano H (2006). Proinflammatory cytokines expression in noise-induced damaged cochlea. J Neurosci Res, 83:575-583.
25. So H, Kim H, Lee JH, Park C, Kim Y, Kim E et al (2007). Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-kappaB. J Assoc Res Otolaryngol, 8:338-355.
26. Sohal RS,Weindruch R (1996). Oxidative stress, caloric restriction, and aging. Science, 273:59-63.
27. Weindruch R, Sohal RS (1997). Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. N Engl J Med, 337:986-994.
28. Marzetti E, Wohlgemuth SE, Anton SD, Bernabei R, Carter CS, Leeuwenburgh C (2009). Cellular mechanisms of cardioprotection by calorie restriction: state of the science and future perspectives. Clin Geriatr Med, 25:715-732.
29. Someya S, Yamasoba T, Weindruch R, Prolla TA, Tanokura M (2007). Caloric restriction suppresses apoptotic cell death in the mammalian cochlea and leads to prevention of presbycusis. Neurobiol Aging, 28:1613-1622.
30. Henry KR (1986). Effects of dietary restriction on presbyacusis in the mouse. Audiology, 25:329-337.
31. Sweet RJ, Price JM,Henry KR (1988). Dietary restriction and presbyacusis: periods of restriction and auditory threshold losses in the CBA/J mouse. Audiology, 27:305-312.
32. Masoro EJ (2000). Caloric restriction and aging: an update. Exp Gerontol, 35:299-305.
33. Lin SJ, Kaeberlein M, Andalis AA, Sturtz LA, Defossez PA, Culotta VC et al (2002). Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration. Nature, 418:344-348.
34. Bishop NA, Guarente L (2007). Two neurons mediate diet-restriction-induced longevity in C. elegans. Nature, 447:545-549.
35. Imai S, Armstrong CM, Kaeberlein M, Guarente L (2000). Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature, 403:795-800.
36. Tanner KG, Landry J, Sternglanz R, Denu JM (2000). Silent information regulator 2 family of NAD- dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc Natl Acad Sci U S A, 97:14178-14182.
37. Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K,Auwerx J (2007). Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann Med, 39:335-345.
38. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I (2005). Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell, 16:4623-4635.
39. Onyango P, Celic I, McCaffery JM, Boeke JD,Feinberg AP (2002). SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci U S A, 99:13653-13658.
40. Schwer B, North BJ, Frye RA, Ott M, Verdin E (2002). The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol, 158:647-657.
41. +-dependent tubulin deacetylase. Mol Cell, 11:437-444.
42. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK et al (2001). hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell, 107:149-159.
43. Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ et al (2006). SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell, 126:941-954.
44. Liszt G, Ford E, Kurtev M, Guarente L (2005). Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J Biol Chem, 280:21313-21320.
45. Shi T, Wang F, Stieren E, Tong Q (2005). SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem, 280:13560-13567.
46. Imai S, Johnson FB, Marciniak RA, McVey M, Park PU, Guarente L (2000). Sir2: an NAD-dependent histone deacetylase that connects chromatin silencing, metabolism, and aging. Cold Spring Harb Symp Quant Biol, 65:297-302.
47. Lin SJ, Ford E, Haigis M, Liszt G, Guarente L (2004). Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev, 18:12-16.
48. Easlon E, Tsang F, Skinner C, Wang C, Lin SJ (2008). The malate-aspartate NADH shuttle components are novel metabolic longevity regulators required for calorie restriction-mediated life span extension in yeast. Genes Dev, 22:931-944.
49. Canto C,Auwerx J (2009). Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab, 20:325-331.
50. Quintas A, de Solis AJ, Diez-Guerra FJ, Carrascosa JM, Bogonez E (2012). Age-associated decrease of SIRT1 expression in rat hippocampus: prevention by late onset caloric restriction. Exp Gerontol, 47:198-201.
51. Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L et al (2005). Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science, 310:314-317.
52. Neumann M, Naumann M (2007). Beyond IkappaBs: alternative regulation of NF-kappaB activity. Faseb J, 21:2642-2654.
53. Yoshizaki T, Milne JC, Imamura T, Schenk S, Sonoda N, Babendure JL et al (2009). SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol, 29:1363-1374.
54. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA et al (2004). Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. Embo J, 23:2369-2380.
55. Levine AJ, Oren M (2009). The first 30 years of p53: growing ever more complex. Nat Rev Cancer, 9:749-758.
56. Kruse JP, Gu W (2009). Modes of p53 regulation. Cell, 137:609-622.
57. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W (2008). Acetylation is indispensable for p53 activation. Cell, 133:612-626.
58. Brooks CL, Gu W (2011). The impact of acetylation and deacetylation on the p53 pathway. Protein Cell, 2:456-462.
59. Li S, Banck M, Mujtaba S, Zhou MM, Sugrue MM, Walsh MJ (2010). p53-induced growth arrest is regulated by the mitochondrial SirT3 deacetylase. PLoS One, 5:e10486.
60. Goodwin PM, Lewis PJ, Davies MI, Skidmore CJ, Shall S (1978). The effect of gamma radiation and neocarzinostatin on NAD and ATP levels in mouse leukaemia cells. Biochim Biophys Acta, 543:576-582.
61. Amaral JD, Xavier JM, Steer CJ, Rodrigues CM (2010). Targeting the p53 pathway of apoptosis. Curr Pharm Des, 16:2493-2503.
62. Vaseva AV, Moll UM (2009). The mitochondrial p53 pathway. Biochim Biophys Acta, 1787:414-420.
63. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D (2010). Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab, 12:662-667.
64. Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C et al. (2010). Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell, 143:802-812.
65. Krishnakumar R, Kraus WL (2010). The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell, 39:8-24.
66. Skidmore CJ, Davies MI, Goodwin PM, Halldorsson H, Lewis PJ, Shall S et al. (1979). The involvement of poly(ADP-ribose) polymerase in the degradation of NAD caused by gamma-radiation and N-methyl-N-nitrosourea. Eur J Biochem, 101:135-142.
67. Bai P, Canto C, Oudart H, Brunyanszki A, Cen Y, Thomas C et al. (2011). PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab, 13:461-468.
68. Rajamohan SB, Pillai VB, Gupta M, Sundaresan NR, Birukov KG, Samant S et al. (2009). SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol Cell Biol, 29:4116-4129.
69. Berger F, Ramirez-Hernandez MH,Ziegler M (2004). The new life of a centenarian: signalling functions of NAD(P). Trends Biochem Sci, 29:111-118.
70. Ido Y (2007). Pyridine nucleotide redox abnormalities in diabetes. Antioxid Redox Signal, 9:931-942.
71. +/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal, 10:179-206.
72. Pearson KJ, Lewis KN, Price NL, Chang JW, Perez E, Cascajo MV et al. (2008). Nrf2 mediates cancer protection but not prolongevity induced by caloric restriction. Proc Natl Acad Sci U S A, 105:2325-2330.
73. Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y et al. (2012). The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab, 15:838-847.
74. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A et al. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444:337-342.
75. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N et al. (2008). Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab, 8:157-168.
76. Minor RK, Baur JA, Gomes AP, Ward TM, Csiszar A, Mercken EM et al. (2011). SRT1720 improves survival and healthspan of obese mice. Sci Rep, 1:70.
77. Mouchiroud L, Houtkooper RH, Auwerx J (2013). NAD(+) metabolism: a therapeutic target for age-related metabolic disease. Crit Rev Biochem Mol Biol, 48:397-408.
78. Ayoub IA, Lee EJ, Ogilvy CS, Beal MF,Maynard KI (1999). Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats. Neurosci Lett, 259:21-24.
79. Ayoub IA,Maynard KI (2002). Therapeutic window for nicotinamide following transient focal cerebral ischemia. Neuroreport, 13:213-216.
80. Brewer KL, Hardin JS (2004). Neuroprotective effects of nicotinamide after experimental spinal cord injury. Acad Emerg Med, 11:125-130.
81. Kaneko S, Wang J, Kaneko M, Yiu G, Hurrell JM, Chitnis T et al. (2006). Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J Neurosci, 26:9794-9804.
82. + and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther, 324:883-893.
83. +. Cell, 129:473-484.
84. + repletion prevents PARP-1-induced glycolytic blockade and cell death in cultured mouse astrocytes. Biochem Biophys Res Commun, 308:809-813.
85. + as a metabolic link between DNA damage and cell death. J Neurosci Res, 79:216-223.
86. Gaikwad A, Long DJ, 2nd, Stringer JL,Jaiswal AK (2001). In vivo role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissue. J Biol Chem, 276:22559-22564.
87. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A,Siegel D (2000). NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact, 129:77-97.
88. Dong H, Shertzer HG, Genter MB, Gonzalez FJ, Vasiliou V, Jefcoate C et al (2013). Mitochondrial targeting of mouse NQO1 and CYP1B1 proteins. Biochem Biophys Res Commun, 435:727-732.
89. Hwang JH, Kim DW, Jo EJ, Kim YK, Jo YS, Park JH et al (2009). Pharmacological stimulation of NADH oxidation ameliorates obesity and related phenotypes in mice. Diabetes, 58:965-974.
90. Kim YH, Hwang JH, Noh JR, Gang GT, Kim do H, Son HY et al (2011). Activation of NAD(P)H:quinone oxidoreductase ameliorates spontaneous hypertension in an animal model via modulation of eNOS activity. Cardiovasc Res, 91:519-527.
91. Kim SY, Jeoung NH, Oh CJ, Choi YK, Lee HJ, Kim HJ et al (2009). Activation of NAD(P)H:quinone oxidoreductase 1 prevents arterial restenosis by suppressing vascular smooth muscle cell proliferation. Circ Res, 104:842-850.
92. Oh GS, Kim HJ, Choi JH, Shen A, Choe SK, Karna A et al (2013). Pharmacological activation of NQO1 increases NAD levels and attenuates cisplatin-mediated acute kidney injury in mice. Kidney Int, 85(3):547-60
93. Lee JS, Park AH, Lee SH, Lee SH, Kim JH, Yang SJ et al (2012). Beta-lapachone, a modulator of NAD metabolism, prevents health declines in aged mice. PLoS One, 7:e47122.